Sellas reports Phase II data for galinpepimut-S in MM

In September, Sellas Life Sciences Group Ltd. (Hamilton, Bermuda) reported data from 20 patients with multiple myeloma (MM) in a Phase II trial showing that galinpepimut-S (WT1 vaccine) led to immune responses, the primary endpoint, of 72-91% to the Wilms tumor 1 (WT1) peptides included in the vaccine. Immune responses against >1 WT1 peptide were detected in up to 66% of patients.

The company said the frequency and potency of CD4 immune responses against the four native WT1 peptides targeted by the vaccine showed a “strong positive correlation” with the rates of complete responses and very good partial responses. Data were presented at the Society of Hematologic Oncology meeting in Houston...